Dendreon (DNDN) Spikes On Presentation News

As discussed, the spike higher in Dendreon Corp. (Nasdaq: DNDN) is related to word that results from the company's prostate cancer drug PROVENGE will be presented at the American Urological Association meeting on Tuesday, April 28. Here is a link to the page announcing the event.

Shares of the often-volatile Dendreon are up 29% on the news. With the crazy trading in this stock, all those gains can be given up in the blink of an eye or it could be up 100% if the "Dendreonians" can get the hype-machine going.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Virtu Financial said to explore $3.5B sales of brokerage unit
• Scorpion Capital says short Twist Biosciences